Status of drug development for the prevention and treatment of osteoporosis

2014 ◽  
Vol 9 (3) ◽  
pp. 245-253 ◽  
Author(s):  
Peter Schwarz ◽  
Niklas Rye Jørgensen ◽  
Bo Abrahamsen
2000 ◽  
Author(s):  
A Cranney ◽  
V Robinson ◽  
G Guyatt ◽  
N Krolicki ◽  
JD Adachi ◽  
...  

Maturitas ◽  
1997 ◽  
Vol 28 (1) ◽  
pp. 95
Author(s):  
J.L. Stock ◽  
L. Amantea ◽  
J.H. Overdorf ◽  
A.D. Samar ◽  
F.L. Pickens

2014 ◽  
Vol 25 (10) ◽  
pp. 2359-2381 ◽  
Author(s):  
F. Cosman ◽  
S. J. de Beur ◽  
M. S. LeBoff ◽  
E. M. Lewiecki ◽  
B. Tanner ◽  
...  

2021 ◽  
Vol 2 (1) ◽  
pp. 15-17
Author(s):  
Maiorova M.O.

41 women with osteoporosis were examined. The age of the examined people ranged from 50 to 60 years. All the women were postmenopausal. As a result of the study, it was found that the most effective management strategy for such patients is a combination of menopausal hormone therapy and non-hormonal drugs that affect calcium metabolism in bone tissue, improve its metabolism and reduce resorption. If there are contraindications to MGT, prevention and treatment of osteoporosis should also be carried out using the appointment of non-hormonal drugs. In this case, the use of ipriflavone is effective.


Sign in / Sign up

Export Citation Format

Share Document